BEX1 acts as a tumor suppressor in acute myeloid leukemia
Metrics: PDF 901 views | HTML 1282 views | ?
Oscar Lindblad1,2,3, Tianfeng Li4, Xianwei Su4,5, Jianmin Sun1,2, Nuzhat N. Kabir6, Fredrik Levander7, Hui Zhao4, Gang Lu4,5, Lars Rönnstrand1,2, Julhash U. Kazi1,2,6
1Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden
2Lund Stem Cell Center, Department of Laboratory Medicine, Lund University, Lund, Sweden
3Department of Hematology and Vascular Disorders, Skåne University Hospital, Lund, Sweden
4School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
5Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
6Laboratory of Computational Biochemistry, KN Biomedical Research Institute, Barisal, Bangladesh
7Bioinformatics Infrastructure for Life Sciences (BILS), Department of Immunotechnology, Lund University, Lund, Sweden
Julhash U. Kazi, e-mail: email@example.com
Keywords: FLT3, FLT3-ITD, AML, apoptosis, AKT
Received: April 16, 2015 Accepted: May 12, 2015 Published: May 26, 2015
Acute myeloid leukemia (AML) is a heterogeneous disease of the myeloid lineage. About 35% of AML patients carry an oncogenic FLT3 mutant making FLT3 an attractive target for treatment of AML. Major problems in the development of FLT3 inhibitors include lack of specificity, poor response and development of a resistant phenotype upon treatment. Further understanding of FLT3 signaling and discovery of novel regulators will therefore help to determine additional pharmacological targets in FLT3-driven AML. In this report, we identified BEX1 as a novel regulator of oncogenic FLT3-ITD-driven AML. We showed that BEX1 expression was down-regulated in a group of AML patients carrying FLT3-ITD. Loss of BEX1 expression resulted in poor overall survival (hazard ratio, HR = 2.242, p = 0.0011). Overexpression of BEX1 in mouse pro-B and myeloid cells resulted in decreased FLT3-ITD-dependent cell proliferation, colony and tumor formation, and in increased apoptosis in vitro and in vivo. BEX1 localized to the cytosolic compartment of cells and significantly decreased FLT3-ITD-induced AKT phosphorylation without affecting ERK1/2 or STAT5 phosphorylation. Our data suggest that the loss of BEX1 expression in FLT3-ITD driven AML potentiates oncogenic signaling and leads to decreased overall survival of the patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.